Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity
Eric Nolen‐Doerr, Mary-Catherine Stockman, Ivania Rizo
Current Obesity Reports (2019) Vol. 8, Iss. 3, pp. 284-291
Closed Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Obesity Management in Adults
Arielle Elmaleh-Sachs, Jessica L. Schwartz, Carolyn T. Bramante, et al.
JAMA (2023) Vol. 330, Iss. 20, pp. 2000-2000
Open Access | Times Cited: 229
Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
Bo Åhrén, Stephen L. Atkin, G. Charpentier, et al.
Diabetes Obesity and Metabolism (2018) Vol. 20, Iss. 9, pp. 2210-2219
Open Access | Times Cited: 110
The Coming Age of Flavonoids in the Treatment of Diabetic Complications
Teresa Caro-Ordieres, Gema Marín‐Royo, Lucas Opazo-Ríos, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 2, pp. 346-346
Open Access | Times Cited: 89
The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review
Khang Duy Ricky Le, Kelvin Le, F F Foo
Pharmacy (2024) Vol. 12, Iss. 1, pp. 11-11
Open Access | Times Cited: 14
Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
Joanna Michałowska, Ewa Miller‐Kasprzak, Paweł Bogdański
Nutrients (2021) Vol. 13, Iss. 2, pp. 351-351
Open Access | Times Cited: 49
Dietary impact on fasting and stimulated GLP-1 secretion in different metabolic conditions – a narrative review
Hanna Huber, Alina Schieren, Jens J. Holst, et al.
American Journal of Clinical Nutrition (2024) Vol. 119, Iss. 3, pp. 599-627
Open Access | Times Cited: 8
S100 proteins in obesity: liaisons dangereuses
Francesca Riuzzi, Sara Chiappalupi, Cataldo Arcuri, et al.
Cellular and Molecular Life Sciences (2019) Vol. 77, Iss. 1, pp. 129-147
Closed Access | Times Cited: 47
Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11
Enzo Bonora, Juan P. Frías, Francisco J. Tinahones, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 10, pp. 2242-2250
Open Access | Times Cited: 40
A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review
Mariana Cornelia Tilinca, Robert Aurelian Tiucă, Alexandru Burlacu, et al.
Medicina (2021) Vol. 57, Iss. 7, pp. 669-669
Open Access | Times Cited: 35
Tetrahydrocurcumin ameliorates diabetes profiles of db/db mice by altering the composition of gut microbiota and up-regulating the expression of GLP-1 in the pancreas
Tianmin Yuan, Zhujun Yin, Zhixiang Yan, et al.
Fitoterapia (2020) Vol. 146, pp. 104665-104665
Open Access | Times Cited: 39
Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients
Paolo Marzullo, T. Daffara, Chiara Mele, et al.
Journal of Endocrinological Investigation (2022) Vol. 45, Iss. 8, pp. 1587-1598
Open Access | Times Cited: 21
Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile
Emir Muzurović, Dimitri P. Mikhailidis
Expert Opinion on Pharmacotherapy (2020) Vol. 21, Iss. 17, pp. 2125-2135
Closed Access | Times Cited: 29
Hypertension in People with Diabetic and Chronic Kidney Disease, Obesity, and Renin Secreting Tumors
Sarah H. Khan, Matthew R. Weir
Updates in hypertension and cardiovascular protection (2025), pp. 33-61
Closed Access
Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial
Matthew C. Riddle, Hertzel C. Gerstein, Denis Xavier, et al.
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 106, Iss. 5, pp. 1345-1351
Open Access | Times Cited: 21
Future perspectives in diabesity treatment: Semaglutide, a glucagon‑like peptide 1 receptor agonist (Review)
Mariana Cornelia Tilinca, Robert Aurelian Tiucă, Cristina Niculas, et al.
Experimental and Therapeutic Medicine (2021) Vol. 22, Iss. 4
Open Access | Times Cited: 19
Differently Expressed Genes (DEGs) Relevant to Type 2 Diabetes Mellitus Identification and Pathway Analysis via Integrated Bioinformatics Analysis
Xuanqiang Che, Ran Zhao, Hua Xu, et al.
Medical Science Monitor (2019) Vol. 25, pp. 9237-9244
Open Access | Times Cited: 20
Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database
Qing Yang, Junyan Wang, Menghuan Wang, et al.
BMC Pharmacology and Toxicology (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 2
Intermittent fasting and neurodegenerative diseases: Molecular mechanisms and therapeutic potential
Renjun Lv, Bin Liu, Ziying Jiang, et al.
Metabolism (2024) Vol. 164, pp. 156104-156104
Closed Access | Times Cited: 2
Uso de análogos de GLP-1 no tratamento da obesidade: uma revisão narrativa / Use of GLP-1 analogues in treatment of obesity: a narrative review
Igor Martins Costa, Jordão Duarte de Almeida, Kamila Marques da Costa, et al.
Brazilian Journal of Health Review (2021) Vol. 4, Iss. 2, pp. 4236-4247
Open Access | Times Cited: 8
Serum GLP-1 and IGF-1 levels are candidate diagnostic biomarkers for type 2 diabetes mellitus complicated by coronary heart disease.
Jingpu Wang, Xue Chen, Yipeng Zhao
PubMed (2023) Vol. 15, Iss. 3, pp. 2033-2039
Closed Access | Times Cited: 3
Prominent and emerging anti-diabetic molecular targets
Faezeh Almasi, Fatemeh Mohammadipanah
Journal of drug targeting (2020) Vol. 29, Iss. 5, pp. 491-506
Closed Access | Times Cited: 6
Glucagon-Like Peptide 1 Receptor Agonist Improves Renal Tubular Damage in Mice with Diabetic Kidney Disease
Ran Li, Dunmin She, Zhengqin Ye, et al.
Diabetes Metabolic Syndrome and Obesity (2022) Vol. Volume 15, pp. 1331-1345
Open Access | Times Cited: 4
Berberine activates the β-catenin/TCF4 signaling pathway by down-regulating miR-106b to promote GLP-1 production by intestinal L cells
Jiao Wang, Li-Rui Wei, Yanling Liu, et al.
European Journal of Pharmacology (2021) Vol. 911, pp. 174482-174482
Closed Access | Times Cited: 5
Flavonoids and Nanotechnology in Insulin Resistance Diabetic Complications
Sanjesh Kumar, Mansi Singh, Pooja S. Murkute, et al.
(2024), pp. 259-316
Closed Access
Uso de medicamentos injetáveis para o emagrecimento
Ingrid de Oliveira Silva, Julia Pereira, Carla Toledo, et al.
Brazilian Journal of Implantology and Health Sciences (2023) Vol. 5, Iss. 3, pp. 876-897
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top